All data from the present study are available from the NSD database ([dx.doi.org/10.18712/NSD-NSD2722-V1](https://dx.doi.org/10.18712/NSD-NSD2722-V1)).

Introduction {#sec001}
============

In accordance with WHO recommendations, Bacillus Calmette-Guérin (BCG) vaccination is normally given at birth in tuberculosis (TB) endemic countries to protect against severe forms of TB \[[@pone.0229287.ref001]\]. Furthermore, BCG vaccination has also been suggested to promote additional non-specific beneficial effects on overall child survival \[[@pone.0229287.ref002], [@pone.0229287.ref003]\]. However, the mechanisms by which BCG may cause this non-specific protective effect is not clear, but recent studies point towards trained immunity as a potential mechanism \[[@pone.0229287.ref004]\]. Trained immunity is a general enhanced long-term responsiveness of innate immune cells to microbial stimuli mediated by monocytes and natural killer (NK) cells \[[@pone.0229287.ref004]\]. β-glucan, a component of the fungal cell wall from *Candida albicans*, has shown to induce training of human monocytes with increased responsiveness not only against fungi, but also against bacteria, viruses and even parasites \[[@pone.0229287.ref004]\]. The mechanism behind this has been by functional, transcriptional and epigenetic reprogramming through a dectin-1/ Raf1-dependent pathway \[[@pone.0229287.ref005], [@pone.0229287.ref006]\].

Monocytes are innate immune cells and an important source of cytokine production during microbial infections. They express a range of pattern recognition receptors, including high expression of Toll-like receptors (TLRs) \[[@pone.0229287.ref007]\]. Newborns are more vulnerable than adults to infections partly due to limited antigenic experience and to the premature status of adaptive immunity in newborns \[[@pone.0229287.ref008]\], placing a greater burden on innate immunity for host defense to microbial challenge in young infants \[[@pone.0229287.ref009]\]. Increased monocyte-derived cytokine responses lasting several months after BCG vaccination have been demonstrated upon *in vitro* stimulation of peripheral blood mononuclear cells (PBMCs) or whole blood with unrelated pathogens or TLR agonists in both infants and adults \[[@pone.0229287.ref010]--[@pone.0229287.ref012]\].

Upon exposure to certain microbial ligands, human monocytes have been shown to undergo trained immunity, both *in vivo* and *in vitro*, via a mechanism of epigenetic reprogramming, resulting in increased responsiveness to secondary stimuli by microbial pathogens and increased cytokine production \[[@pone.0229287.ref010], [@pone.0229287.ref013]\].

BCG and β-glucan have been shown to induce trained immunity in adult monocytes \[[@pone.0229287.ref014]\] in a well-known model of *in vitro* induction of trained immunity. However, little is known about the capacity of neonatal monocytes to maintain immunological information from a previous antigenic experience. In this study, making use of this model \[[@pone.0229287.ref014]\], we aimed to investigate whether human cord blood adherent monocytes (CBAM) possess, similar to adult peripheral blood adherent monocytes, the capacity to adapt their cytokine production after previous exposure to BCG and β-glucan.

Materials and methods {#sec002}
=====================

Study participants {#sec003}
------------------

In total, 45 participants were recruited. Umbilical cord blood (CB) from 15 newborn full term babies were collected at the maternity ward of Haukeland Hospital, Bergen, Norway. We obtained informed consent from pregnant mothers. Eligibility requirements included pregnant mothers who were to deliver by cesarean section. Mothers were approached and the study purpose explained to them in a language they could understand. Those who gave informed consent on behalf of their newborn babies were recruited in the study. Mothers with known blood transmitted infections were not included in the study. For every neonate, peripheral blood samples from two healthy adults in a volunteer pool of 30 adults were collected. Exclusion criteria were any blood disorders, immunodeficiencies or any medication that would affect the immune system. BCG vaccination status for 27 adult volunteers was known. Out of these, 22 had been vaccinated, all of them more than 10 years ago, (until 2005 Norwegians were vaccinated at around age 10--14 years) while 5 adults were not vaccinated.

Ethical considerations {#sec004}
----------------------

Ethical approval was obtained from the Ethics committee at Haukeland Hospital, Bergen, Norway. All the participants consented to take part in the study.

Experimental methods {#sec005}
--------------------

Cord and adult samples were collected in Acid Citrate Dextrose (ACD) tubes, and obtained within a mean 4 (range 3--5) hour timeframe. They were processed simultaneously, under the same conditions.

Placental cord blood mononuclear cells (CBMCs) and adult peripheral blood mononuclear cells (PBMCs) were isolated by Lymphoprep (GE Healthcare, UK) using density centrifugation from blood diluted 1:2 in sterile phosphate-buffered saline (PBS). Cells were washed three times in cold PBS and the pellet was re-suspended in 1ml of Dutch modified Roswell Park Memorial Institute Medium (RPMI-1640) culture medium (Invitrogen, CA, USA) supplemented with 50 μg/mL gentamicin, 20 mM GlutaMAX, and 10 mM pyruvate.

*In vitro* assay of adherent monocytes {#sec006}
--------------------------------------

A total of 5 × 10^5^ mononuclear cells in a 100 μl volume were added to polystyrene flat-bottom 96-well plate (Corning, NY, USA) for 1 hr at 37°C for monocytes to adhere and cells were washed three times with warm PBS to remove non-adherent cells \[[@pone.0229287.ref014]\]. The adhered monocytes were then cultured at 37°C in RPMI supplemented with 10% pooled sterile human serum. During the first 24 hours cells were primed by being cultured with either live-attenuated BCG Bulgaria (Intervax, Sofia, Bulgaria) (5ug/ml) or the *Candida albicans* (*C*. *albicans*) cell wall component β-glucan (1ug/ml), a potent inducer of trained immunity which was kindly provided by Professor David Williams (East Tennessee State University, USA) \[[@pone.0229287.ref014]\], or cultured with RPMI only as negative control. After 24 hours the plates were washed once with 200 μL warm PBS. The culture medium was changed on day 4. On day 6 the cells were re-stimulated with *Escherichia coli* LPS (Serotype O55:B5, Sigma-Aldrich, St. Louis, MO, USA) (10 ng/ml) or left unstimulated. On day 7, supernatants were harvested and stored at −80°C.

Cytokine measurements {#sec007}
---------------------

IL-6, IL-10 and TNF were measured in stored supernatants using commercial Duoset ELISA kits (R&D Systems MN, USA) according to the manufacturer's instructions.

Statistical analyses {#sec008}
--------------------

Cytokine responses were analyzed by calculating the fold change (measured stimulated cytokine values were divided by the values for the RPMI-only wells. Data were not normally distributed. We therefore, used the Wilcoxon matched-pairs sign-rank-test for comparisons of cytokine responses in trained monocytes to values in the RPMI-only well cultures. Mann-Whitney non-parametric test (Wilcoxon-rank-sum-test) was used to compare cytokine levels between adults and neonates.

The statistical analyses were performed in STATA version 15 (StataCorp. 2009; Stata Statistical Software, College Station TX) and graphs were drawn using GraphPad Prism 7 (Graph Pad Software, Inc., San Diego, CA, USA). A two-tailed p value was considered significant if \< 0.05.

Results {#sec009}
=======

Adult volunteers in the study had a mean age of 43 years (range 20--67), with 66% being female. Neonate samples were completely anonymized, thus gender was not available for this group.

Cytokine profiles to LPS following BCG and β-glucan priming in neonates {#sec010}
-----------------------------------------------------------------------

We examined cytokine production from CBAM stimulated with BCG or β-glucan, then re-stimulated with LPS on day 6 and compared their cytokine production capacity with unprimed, LPS re-stimulated conditions.

There was a significant increase in IL-6 production following BCG priming in neonates, but TNF and IL-10 production were not different. ([Fig 1A](#pone.0229287.g001){ref-type="fig"}). β-glucan priming resulted in a significant increase of all cytokine levels IL-6, IL-10 and TNF tested ([Fig 1A](#pone.0229287.g001){ref-type="fig"}).

![Cytokine profiles to LPS following BCG and β-glucan priming as compared to medium control conditions (A) In neonates, IL-6 (n = 15) cytokine production significantly increased in BCG-primed monocytes. (B) In adults, IL-6 (n = 30) production after LPS re-stimulation increased significantly after BCG priming. β-glucan priming of monocytes led to a significant increase of all cytokine levels (IL-6, IL-10 and TNF) in both neonates and adults. \*P \< .05; \*\*P \< .01; \*\*\*P \< .001.](pone.0229287.g001){#pone.0229287.g001}

The middle horizontal lines represent the median; boxes cover 50% of the values between the 25th and the 75th percentiles, with the lower 25% and upper 75% percentiles. Abbreviations: BCG, Bacillus Calmette-Guérin; IL, interleukin; TNF, tumor necrosis factor; LPS, Lipopolysaccharide; RPMI, Roswell Park Memorial Institute medium.

Cytokine profiles to LPS following BCG and β-glucan priming in adults {#sec011}
---------------------------------------------------------------------

Similar to the data for infant cytokine responses, adult peripheral blood adherent monocytes primed with BCG induced increased levels of IL-6 and β-glucan initial stimulation led to significantly increased concentrations of IL-6, IL-10 and TNF ([Fig 1B](#pone.0229287.g001){ref-type="fig"}).

The magnitude of cytokine profiles between neonates and adults {#sec012}
--------------------------------------------------------------

Cytokine responses were generally of similar magnitude in adults and neonates. Cytokine production between neonates and adults following either BCG or β-glucan training was compared for each of the three cytokines. We did not observe significant differences in production of the three cytokines tested following initial stimulation with either BCG or β-glucan.

Discussion {#sec013}
==========

Monocytes play an important role in BCG-induced trained immunity in adults \[[@pone.0229287.ref010]\]. Induction of non-specific innate immunological memory is a mechanism proposed to explain non-specific beneficial effects in neonates after BCG vaccination \[[@pone.0229287.ref011]\].

In the present study we show a change in cytokine production in both neonatal and adult monocytes, with upregulation of IL-6 production in response to LPS after initial BCG and β-glucan exposure.

This is the first study to investigate the capacity of CBAM to respond with altered cytokine production and whether it is to a similar degree as adult monocytes. Our data shows that some CBAM cytokine responses, when re-stimulated with LPS following initial priming with either BCG or β-glucan stimuli, are increased compared to LPS-re-stimulated non-primed CBAM. We also demonstrate that β-glucan can induce changes in cytokine production in CBAM in a way similar to adult adherent monocytes through increased production of the three cytokines tested (IL-6, IL-10, and TNF) after re-stimulation with LPS.

Bekkering *et al*, showed that β-glucan priming increased not only pro-inflammatory cytokine production (IL-6 and TNF) but also anti-inflammatory cytokine (IL-10 and IL-1Ra) production following resting of cells for 6 days. These findings are similar to the current study that shows a significant increase of all cytokines (IL-6, IL-10, and TNF) following β-glucan training.

In a previous study of peripheral blood adherent monocytes from adults, using a similar protocol as conducted in our current study, increased production of TNF following initial BCG training and re-stimulation with LPS was reported \[[@pone.0229287.ref010]\]. In the current study, the increase in TNF in adults did not reach significance and further comparison is difficult because IL-6 and IL-10 were not measured in the previous study. In the previous studies by Bekkering *et al* and Kleinnijenhuis *et al* BCG Denmark was used, while for the present study BCG Bulgaria strain was used instead, due to production shortages at SSI-Denmark, and lack of availability of BCG-Denmark strain. Several studies have found BCG Denmark to be more immunoreactive than BCG Bulgaria \[[@pone.0229287.ref015], [@pone.0229287.ref016]\]. However, whether this affects the ability to induce alterations in cytokine response is not known. Further studies utilizing the adherent monocyte model could be a feasible *in vitro* model to compare the ability of various BCG strains to induce trained responses.

Other studies have demonstrated increased IL-6, IL-1β, TNF, IL-10 and IFN-γ cytokine responses after BCG vaccination upon later *ex vivo* non-mycobacterial stimulation in both infants and adults \[[@pone.0229287.ref010]--[@pone.0229287.ref012]\]. In infants, it has been demonstrated that BCG vaccination led to significantly increased levels of IL-6 and IL-10 after *in vitro* whole blood stimulation with non-related microbial stimuli four months later, but not of TNF \[[@pone.0229287.ref011]\]. These findings suggest that trained immune responses to BCG may last for several months.

A randomized trial of low birth weight infants receiving BCG at birth measured cytokine responses to innate agonists like LPS in whole-blood assays after 4 weeks. BCG vaccination was associated with increased cytokine levels, particularly of IL-1β, IL-6, TNF, and IFN-γ, but no significant effect was detected at the level of IL-10 production \[[@pone.0229287.ref012]\]. These results concur with our current *in vitro* results after BCG priming, except that we did not see a significant rise in TNF levels.

A number of previous studies have revealed the epigenetic and metabolic mechanisms underlying the increased responsiveness in trained immunity using the present model \[[@pone.0229287.ref010], [@pone.0229287.ref014], [@pone.0229287.ref017]\]. Such further characterization of the broad trained immunity phenotype of cord blood adherent monoctes was beyond the scope of the present study, and was not assessed. However, further studies may look into potential differences in these mechanisms between neonates and adults.

Although there are differences between umbilical cord blood and venous blood from adults, adherent cells were isolated in the same way. It should be noted that non-immune cells, such as mesenchymal and hematopoietic stem cells, are present in umbilical cord blood and have adhesive properties. Such cells have shown the potential to be trained \[[@pone.0229287.ref018]\]. However, they are very few in number and therefore unlikely to cause bias in the observed cytokine profile. A study by Normann *et al*, showed a profile of CBAM with a purification of non‐active but stimulation‐competent monocytes with high yields (2.3--9×10^7^ cells) and purity of 70--90% (average 83%) by adherence or 90--98% by flow cytometric analysis \[[@pone.0229287.ref019]\].

We acknowledge that cord blood monocytes may not be equivalent to neonatal peripheral blood monocytes. However, we did not identify any studies that have examined this question and therefore this should be investigated in future studies.

The results of this study indicate that this *in vitro* model of trained immunity is applicable also in neonates and therefore may be helpful in evaluating present and future vaccine candidates with regard to their heterologous innate immune effects. Including measurement of epigenetic and metabolic alterations in such experiments are important to characterize the nature of the effects and mechanisms behind them.

Conclusion {#sec014}
==========

Our findings show that BCG vaccine is capable of inducing increased cytokine production, reminiscent of trained immunity, in cord blood adherent monocytes. BCG vaccination at birth may therefore modulate the development of the neonatal immune system and may play a role in the non-specific effects of BCG observed in epidemiological studies.

We appreciate the adult volunteers and mothers who consented for their babies to be involved in the study. Thanks to the research colleagues at Haukeland University hospital who assisted with cord blood collection and to Victoria Nankabirwa for useful comments to the manuscript.

10.1371/journal.pone.0229287.r001
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Reviewer \#1: This very basic study compared BCG and beta-glucan-induced cytokine expression by monocytes cultured from cord blood to monocytes from adult peripheral blood.

The cytokine expression by monocytes in response to BCG exposure was very modest and IL-6 was increased only. The title of this article states focuses only on the BCG response; however my opinion is that more data are required to convincingly show that these cord blood monocytes have been \'trained\' (e.g. metabolic changes/epigenetic changes) beyond a very modest increase in a single cytokine.

Regarding the authors\' conclusions: Are cord blood monocytes phenotypically equivalent to neonatal peripheral blood monocytes? The authors imply this is the case.
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We, however, acknowledge that both IL-6 and TNF levels were increased in monocytes isolated from anonymous blood donors following BCG training in a similar in vitro assay in Kleinnijenhuis 2012 (1) and Bekkering 2016 (2). In the Bekkering paper, IL-6 responses were about 5 fold higher after 24h BCG training and later LPS restimulation, while TNF responses were about 2-fold higher. IL-10 responses did not reach significance. Encouraged by the above question we have from reviewers 1 and 2 we have added a paragraph in the manuscript discussing whether a less reactive BCG strain (BCG Bulgaria) was used in the present study. In both Kleinnijenhuis 2012 and Bekkering 2016, the BCG Denmark vaccine strain was used. Although it has not been tested for potential differences in inducing trained immunity, BCG Denmark has been shown to be more reactive and inducing higher cytokine levels upon homologous and heterologous stimulation (Anderson 2012, Ritz 2012) (3,4) This is likely the reason for weaker responses to BCG in both neonate and adults in our study, with only IL-6 being significant.
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For 27 adult volunteers vaccination status was known. 22 had been vaccinated, all of them many years ago, (until 2005 Norwegians were vaccinated at around age 10-14 years). 5 adults were not vaccinated. Responses in vaccinated and unvaccinated were generally similar, with the small group of 5 non-vaccinated tending to have slightly higher median responses than the vaccinated. With the long time since vaccination and similar responses in vaccinated and unvaccinated volunteers, we believe vaccination status is unlikely to have influenced results.

Reviewer \#2: Authors describe an experiment evaluating the cytokine produced after LPS stimulation adherent cells from cord blood and adult venous blood that were either non-primed or primed with BCG or B-glucan. Both BCG and B-glucan can \"train\" innate immune cells, essentially the response to a secondary stimulus (typically a TLR agonist) is increased in trained cells over non-trained cells. Much of the data to date has focused on adults, and maybe children, the ability of mononuclear cells (primarily monocytes) to undergo innate training has not been demonstrated. The use of cord blood provides one mechanism to evaluate neonate monocyte ability to undergo training.

Overall, the intent of the study was a single question, and with some improvements to writing, describes training potential of neonatal cells.

Comments:

More differences were observed with B-glucan than BCG, yet the title only mentions BCG, and discussion is focused on BCG. Inclusion of B-glucan into the title, abstract, intro, and discussion are warranted. The b-glucan findings are just as important. Some revision for verb tense is warranted. New data should be past tense, and established (ie, published data) is present tense.

We agree. We have now included β-glucan in the title, abstract, intro and added discussion of these findings in the discussion as advised and the revision for verb tense has been done.

Line 69 references children and adults, line 74 only refers to adults.

Line 69 refers to some of the studies that have demonstrated trained innate immunity in both children and adults. However, line 74 describes the in vitro induction of trained immunity model which was studied in adults but not neonates, hence the reason for us to study this model in neonates.

Is data from children the better comparison? Perhaps best to clearly define by age neonate to children?

There is hardly data on trained innate immunity of adherent mononuclear cells in neonates.

We agree that it is better to change \"children\" to \"infants\" as shown in a few studies done in infants; Smith SG et al, 2017 (5) and Jensen KJ, et al, 2015 (6). These studies however, didn\'t use adherent monocytes and were post-vaccination studies.

To be more specific we have changed the word "children" to "infants" in the introduction.

Line 116 -- is it a company or a lab that provided the BCG? It only reads as TN, USA which is unclear.

The reviewer here obviously meant β-glucan and not BCG. β-glucan was kindly provided by Professor David Williams (East Tennessee State University, USA). We have corrected this in the Methods section.

Line 129 -- define the negative control -- you mean RPMI-only wells?

Same for Line 132

Yes, the negative control is the RPMI- only wells. We have now defined it more clearly in the mentioned paragraphs.

Graph titles may be better presented at top of graph, versus below. Can the cytokine name be moved to the top (as opposed to below?).

We thank the reviewer for good suggestions. The figures have been improved accordingly.

Line 148 -- given how the data is presented (expressed as fold change) the use of the words "remained stable" are misleading. Perhaps it's "were not different" instead, as remained stable suggests the cytokine was produced (and perhaps it was, but with normalization to RPMI-only group, that cannot be visualized.

Yes, we agree that "were not different" is a clearer formulation. This has been corrected in the revised manuscript.

Expand on line 150 to include name of all three cytokines.

Naming of all three cytokines has been included.

Line 144 and 161 warrant revision for clarity -- the response isn't to BCG or B-glucan, it's to LPS after prior BCG or B-glucan exposure. Include the word training or expand to say "...to LPS following BCG or B-glucan priming"

We agree. This has been corrected to include "to LPS following BCG or β-glucan priming"

Line 170 -- this means you did statistics between the adult and neonate for each respective treatment?

Yes, to help make this clearer we rephrased sentences about comparison between adults and neonates.

Line 181 -- that data is not shown. The response to LPS would be in the RPMI only group or the RPMI+LPS group? As a reader, we cannot appreciate the response of CBAM to LPS because that was used as the normalizer. Perhaps it's an important point in general if the same amount of IL6 is produced by non-trained cells after LPS stimulation. The sentence warrants revision for clarity.

We agree that this sentence can be better formulated to reflect the presented data. The production of cytokines in the BCG and β-glucan primed cells that were restimulated with LPS were normalized against the cytokine production in the non-primed (RPMI only) LPS-restimulated cells. For more information: there was cytokine production in the non-primed cell cultures used for normalization, and this was similar in adults and neonates; i.e. for any of the three cytokines, measured levels of non-primed, LPS-restimulated monocytes were not significantly different in adult and neonates.

In the revised manuscript, the inserted sentence "and that CBAM respond to LPS re-stimulation" has been removed for clarity.

This is also true for the following sentence into line 182 -- CBAM response to LPS can be maintained following initial training -- again, left to infer that cytokine was produced, but because of the normalization of the data, that is not apparent. We just know it wasn't different between non-trained (RPMI only) and BCG primed (or trained) cells.

We agree and have clarified the sentence to "Our data shows that some CBAM cytokine responses, when restimulated with LPS following initial training with either BCG or β-glucan stimuli, are increased compared to LPS-restimulated non-trained CBAM." as this is what we want to show by calculating and presenting our data as fold change.

Line 192 -- can the authors try to explain why there may be a difference? It's nice they can contrast to prior studies, but why is this study different? Was the source of BCG different between the two studies?

We note that TNF and IL-10 cytokines did not show significant increase following BCG exposure in neither adults nor neonates in our study.

We, however, acknowledge that both IL-6 and TNF levels were increased in monocytes isolated from anonymous blood donors following BCG training in a similar in vitro assay in Kleinnijenhuis 2012 (1) and Bekkering 2016 (2). In the Bekkering paper, IL-6 responses were about 5 fold higher after 24h BCG training and later LPS restimulation, while TNF responses were about 2-fold higher. IL-10 responses did not reach significance. Encouraged by the above question we have from reviewers 1 and 2 we have added a paragraph in the manuscript discussing whether a less reactive BCG strain (BCG Bulgaria) was used in the present study. In both Kleinnijenhuis 2012 and Bekkering 2016, the BCG Denmark vaccine strain was used. Although it has not been tested for potential differences in inducing trained immunity, BCG Denmark has been shown to be more reactive and inducing higher cytokine levels upon homologous and heterologous stimulation (Anderson 2012, Ritz 2012) (3,4) This is likely the reason for weaker responses to BCG in both neonate and adults in our study, with only IL-6 being significant. The reason for the use of BCG Bulgaria strain in the current study was represented by the production problems at SSI Denmark during the performance of the study, with BCG-Denmark strain not being available between 2016-2019.

Another difference was use of different concentrations of BCG. In Kleinnijenhuis 2012 and Bekkering 2016 studies, they used 1µg/mL and 10µg/mL, respectively, while in the current study we used 5µg/mL.

Line 210 warrants a citation or a profile of CBAM -- what percentage of what remains in the dish is expected or shown to be other cell types that would not be present using adult venous blood? Most of the data coming from the mouse world shows such tight error bars and similar responses with training. The human data set has greater differences, acknowledgement in the discussion is warranted. Is this genetics, or exposure to immune altering compounds in utero?

We agree that this is a fair discussion point. A profile of CBAM in a study by Normann Erik et al, showed a purification of non‐active, but stimulation‐competent monocytes with high yields (2.3--9×107 cells) and purity of 70--90% (average 83%) by adherence or 90--98% by flow cytometric analysis (7).

We have added this issue and the reference in the Discussion.

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?<https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history>). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy<https://www.plos.org/privacy-policy>.

Reviewer \#1: No

Reviewer \#2: No

Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using

PACE, please email us at <figures@plos.org>\<mailto:<figures@plos.org>\>.

Please note that Supporting Information files do not need this step.
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Monocytes from neonates and adults have a similar capacity to elicit trained immunity responses to BCG and β-glucan

PLOS ONE

Dear Dr Hanevik,

Thank you for resubmitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Based on the reviewer comments, some issues were not directly addressed, thus please pay careful attention to these comments.

We would appreciate receiving your revised manuscript by Dec 20 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Angelo A. Izzo

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: My original major concern remains: I do not feel it is sufficient to term cytokine production by monocytes \'training\' without showing additional features that are characteristic of innate immune training (eg switch in metabolism to glycolysis, epigenetic changes, other functional changes such as reactive oxygen species production or the longevity of the response). The authors have not addressed this concern and should do so by re-considering their aims and conclusions. The cytokine production may indicate in vitro training, but the authors do not provide any evidence that this was the case and need to acknowledge this.

The authors should include the vaccination status of the adult volunteers in the Methods.

Title: revisit - is this really training?

Abstract: L38 - this study does not address the ability of BCG and beta-glucan to induce trained immunity in neonates. It studies the ability of BCG and beta-glucan to induce cytokine production in cord blood monocytes.

Typographical errors:

L55 - use the abbreviation TB

L154 females \--\> female

L163 cytokine levels \--\> cytokines (IL-6, \...)

L213 - replace the \'the\'

L247 - \... therefore this should be \...

L248 The Results \--\> The results

Tenses are still a bit confused in the discussion - established knowledge/data in the present tense, but when you refer to a specific study (published or not) use the past tense.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

14 Nov 2019

Professor Angelo A. Izzo November 11th, 2019

Editor

PLoS ONE,

Dear Professor Izzo

PONE-D-19-19049R1

Responses to Reviewer's comments regarding the submitted manuscript entitled "Monocytes from neonates and adults have a similar capacity to elicit trained immunity responses to BCG".

Thank you very much for the positive assessment to our revised submitted manuscript. Please find responses to the reviewer's comments to our revised manuscript. The manuscript has been revised according to many of the comments. We thank the reviewers for taking the time to point out some grammatical improvements.

Comments to the Author

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: (No Response)

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: (No Response)

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy<http://www.plosone.org/static/policies.action#sharing> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: (No Response)

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: My original major concern remains: I do not feel it is sufficient to term cytokine production by monocytes \'training\' without showing additional features that are characteristic of innate immune training (eg switch in metabolism to glycolysis, epigenetic changes, other functional changes such as reactive oxygen species production or the longevity of the response). The authors have not addressed this concern and should do so by re-considering their aims and conclusions. The cytokine production may indicate in vitro training, but the authors do not provide any evidence that this was the case and need to acknowledge this.

Answer. This is an important point that is raised by the reviewer. Strictly, the term of trained immunity depicts the long-term capacity of innate immune cells to over-respond to a second stimulation, after the short-term exposure to an initial stimulus. The marker of that is generally used is cytokine production, while the mechanisms behind it are metabolic and epigenetic. This has been shown by measuring cytokines in a number of studies, and the in vitro model we use it has been described for adults.

We have now used the same model in cord blood monocytes. The experimental method used in this study is an in vitro model of trained immunity published in several papers (Kleinnijenhuis et al., 2012, Arts et al 2016 and Bekkering et al 2016). In addition to measuring cytokine responses as proof of training, the mentioned studies also used the model to investigate the metabolic and epigenetic mechanisms related to trained immunity. Although this would have been interesting as added measurements of trained immunity, our focus in the present study was to compare adult and cord blood monocyte trained immune responses in a well-established model with the commonly used immunological readouts of trained immunity. Not enough material is unfortunately currently available to extend these studies to metabolic and epigenetic parameters.

We have addressed the reviewers concern by stating in the discussion that epigenetic and metabolic changes to further define a 'broad trained immunity phenotype' was not done in this study. In the immunological sense, showing hyper-responsiveness is enough to demonstrate trained immunity.

The authors should include the vaccination status of the adult volunteers in the Methods.

Answer. We have now included vaccination status of adults in methods section of the revised manuscript.

Title: revisit - is this really training?

Answer. Based on the arguments exposed above, we argue that the process studied in this ex-vivo model is indeed training, both by definition and by readouts in an established model for trained immunity.

Abstract: L38 - this study does not address the ability of BCG and beta-glucan to induce trained immunity in neonates. It studies the ability of BCG and beta-glucan to induce cytokine production in cord blood monocytes.

Answer. In our opinion "the ability of BCG and beta-glucan to induce cytokine production in cord blood monocytes", when restimulated with LPS after a resting period is per definition a trained immunity response as seen in this model in several studies and the way this term is used in the current literature. We do not merely study the direct responsiveness of cord blood monocytes to acute stimulation. We therefore believe the text in the abstract reflects this correctly.

However, we agree that replacing the term "neonates" with "cord blood monocytes" in this sentence states the aim in a more specific way, and this has been replaced in the abstract.

Typographical errors:

L55 - use the abbreviation TB

The abbreviation 'TB' has been used instead of 'tuberculosis' in the revised manuscript.

L154 females \--\> female

This error has been corrected.

L163 cytokine levels \--\> cytokines (IL-6, \...)

The cytokines (IL-6, IL-10 and TNF) have been mentioned in the revised manuscript.

L213 - replace the \'the\'

'the' has been replaced in the manuscript

L247 - \... therefore this should be \...

The sentence has been revised in the manuscript

L248 The Results \--\> The results

This has been corrected in the manuscript

Tenses are still a bit confused in the discussion - established knowledge/data in the present tense, but when you refer to a specific study (published or not) use the past tense.

Thanks for this observation; tenses in the discussion have been revised once again in the revised manuscript

Reviewer \#2: (No Response)

7\. PLOS authors have the option to publish the peer review history of their article (what does this mean?<https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history>). If published, this will include your full peer review and any attached files

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy<https://www.plos.org/privacy-policy>.

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>\<mailto:<figures@plos.org>\>. Please note that Supporting Information files do
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PONE-D-19-19049R2

Monocytes from neonates and adults have a similar capacity to elicit trained immunity responses to BCG and β-glucan

PLOS ONE

Dear Dr Hanevik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Feb 01 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Angelo A. Izzo

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors strongly argue that what they observe (increased cytokine production) is trained immunity. That may be true; however I still have concerns about this, not least because the responses are quite different (perhaps due to the BCG strain used) from previously published data. This could mean that the \'training\' (ie epigenetic/metabolic changes etc) observed in the earlier published work did not occur here. In order to feel satisfied accepting this I think the authors should restrain their conclusions (ie in the abstract instead of saying \"BCG and B-glucan induce a similar level of trained immunity in neonatal monocytes\" they should more carefully state \"BCG and B-glucan induce increased cytokine production, reminiscent of trained immunity, in neonatal monocytes\". I understand it is not possible to do further testing on the samples; however simply measuring cytokines is insufficient to indicate trained immunity, especially when the results are different (diminished) compared to the published work using this model.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229287.r006

Author response to Decision Letter 2

23 Dec 2019

PONE-D-19-19049R2

Responses to comment from Reviewer\#1 regarding the resubmitted manuscript entitled "Monocytes from neonates and adults have a similar capacity to elicit trained immunity responses to BCG".

Reviewer \#1: The authors strongly argue that what they observe (increased cytokine production) is trained immunity. That may be true; however I still have concerns about this, not least because the responses are quite different (perhaps due to the BCG strain used) from previously published data. This could mean that the \'training\' (ie epigenetic/metabolic changes etc) observed in the earlier published work did not occur here.

In order to feel satisfied accepting this I think the authors should restrain their conclusions (ie in the abstract instead of saying \"BCG and B-glucan induce a similar level of trained immunity in neonatal monocytes\" they should more carefully state \"BCG and B-glucan induce increased cytokine production, reminiscent of trained immunity, in neonatal monocytes\".

I understand it is not possible to do further testing on the samples; however simply measuring cytokines is insufficient to indicate trained immunity, especially when the results are different (diminished) compared to the published work using this model.

Reply: We agree we could be a little more cautious in the interpretation and have changed the relevant sentences in conclusions in the abstract and manuscript in line with the reviewer's request.

To further underline the issue raised by the reviewer we also added the sentence "Including measurement of epigenetic and metabolic alterations in such experiments will be helpful to characterize the nature of the effects and mechanisms behind them" in the discussion about further experiments.

###### 

Submitted filename: Rebuttal letter 23Des19.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0229287.r007
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© 2020 Angelo A. Izzo

2020

Angelo A. Izzo

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

14 Jan 2020

PONE-D-19-19049R3

Monocytes from neonates and adults have a similar capacity to elicit trained immunity responses to BCG and β-glucan

PLOS ONE

Dear Dr Hanevik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Feb 28 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Angelo A. Izzo

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

I strongly recommend that you read the comments made by Reviewer 1 and make the changes requested.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have made some quite minor amendments to the manuscript to address my concern, which is that I think it is incorrect to use the term \'trained immunity\', without evidence of this beyond cytokine production particularly given that the cytokine responses observed in this study differed to those from the cited earlier publications that use the \'well-established\' model.

This authors can address this by properly restraining conclusions in the title, abstract and full manuscript; however the authors have only made a small attempt to do this and in my opinion most people giving this manuscript a cursory read, as it stands, would not notice that other aspects of training (beyond cytokine production) have not been determined and it is relying on previous published work.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229287.r008

Author response to Decision Letter 3

22 Jan 2020

Reviewer \#1: The authors have made some quite minor amendments to the manuscript to address my concern, which is that I think it is incorrect to use the term \'trained immunity\', without evidence of this beyond cytokine production particularly given that the cytokine responses observed in this study differed to those from the cited earlier publications that use the \'well-established\' model.

This authors can address this by properly restraining conclusions in the title, abstract and full manuscript; however the authors have only made a small attempt to do this and in my opinion most people giving this manuscript a cursory read, as it stands, would not notice that other aspects of training (beyond cytokine production) have not been determined and it is relying on previous published work

Response: In the previous revision, we introduced the changed requested by the reviewer. When it is now requested to make more thorough revision of the use of the term "trained immunity" we have discussed this between us and acknowledge that there are different opinions regarding the use of this term.

In addition to the already introduced cautious wording "reminiscent of trained immunity", as advised by the reviewer previously, we have therefore now revised the manuscript to focus on presenting the cytokine response data. We have used more cautious wording and made amendments to the revised manuscript with properly restraining conclusions regarding "trained immunity" in the title, abstract and full manuscript.

###### 

Submitted filename: Rebuttal letter 22Jan20.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0229287.r009
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4 Feb 2020

Monocytes from neonates and adults have a similar capacity to adapt their cytokine production after previous exposure to BCG and β-glucan

PONE-D-19-19049R4

Dear Dr. Hanevik,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Angelo A. Izzo

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

10.1371/journal.pone.0229287.r010
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Creative Commons Attribution License
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10 Feb 2020

PONE-D-19-19049R4

Monocytes from neonates and adults have a similar capacity to adapt their cytokine production after previous exposure to BCG and β-glucan

Dear Dr. Hanevik:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Angelo A. Izzo

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
